Nature Mental Health
May 1, 2026
Daniel Bello, Sophia H. Blyth, Rachel A Rabin et al.
Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco (‘co-use’) is rising in the general population, but has not been studied in psychosis. Given the devastating consequences of cannabis and tobacco use, it is critical to understand how their co-use affects psychiatric...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
April 1, 2026
Daniel Bello, J. Connolly, Jean Addington et al.
BACKGROUND Cannabis use is highly prevalent among people with psychotic disorders. While there is some indication that cannabis use exacerbates psychosis symptoms, its neurocognitive effects remain unclear. Co-use of cannabis and tobacco is increasing in the general population, but little is known about its effects in people with psychosis or those at risk for developing a psychotic disorder,...
Schizophrenia Research
July 30, 2024
L. Kennedy, B. Ku, Jean Addington et al.
Background: Neurocognitive deficits have been widely reported in clinical high-risk for psychosis (CHR) populations. Additionally, rates of cannabis use are high among CHR youth and are associated with greater symptom severity. Cannabis use has been sometimes shown to be associated with better neurocognition in more progressed psychosis cohorts, therefore in this study we aimed to determine...
Psychological Medicine
2024
Simon Kapler, Laura Adery, Gil D Hoftman et al.
Cannabis use is consistently associated with both increased incidence of frank psychotic disorders and acute exacerbations of psychotic symptoms in healthy individuals and people with psychosis spectrum disorders. Although there is uncertainty around causality, cannabis use may be one of a few modifiable risk factors for conversion to psychotic disorders in individuals with Clinical High Risk...
Journal of Consulting and Clinical Psychology
April 2023
Marc J. Weintraub, Danielle Denenny, Megan Ichinose et al.
There is substantial evidence that cognitive behavioral therapy (CBT) and mindfulness-based cognitive therapy (MBCT) improve symptoms and functioning in adults with mood and psychotic disorders. There has been little work directly comparing these treatments among adolescents with early-onset mood or psychosis symptoms. We conducted a randomized controlled trial comparing remotely administered...
Schizophrenia Research
August 25, 2022
Olga Santesteban-Echarri, Lu Liu, Madeline Miller et al.
Cannabis use is more prevalent among youth at clinical high-risk (CHR) for psychosis than healthy controls (HC). There is mixed evidence as to whether cannabis use is associated with increased severity of attenuated psychotic symptoms (APS) or whether current cannabis use is associated with the transition to psychosis. This study aims to assess cannabis use differences between CHR youth and HC...
Psychiatry Research
November 25, 2015
L. Buchy, L. Seidman, Kristin Cadenhead et al.
Among people with psychosis, those with a history of cannabis use show better cognitive performance than those who are cannabis naïve. It is unknown whether this pattern is present in youth at clinical high risk (CHR) of psychosis. We evaluated relationships between IQ and cannabis use while controlling for use of other substances known to impact cognition in 678 CHR and 263 healthy control...
Acta Psychiatrica Scandinavica
January 9, 2015
Andrea M. Auther, Kristin Cadenhead, Ricardo E Carrión et al.
46 citations
OBJECTIVE: Cannabis use has been examined as a predictor of psychosis in clinical high-risk (CHR) samples, but little is known about the impact of other substances on this relationship. METHOD: Substance use was assessed in a large sample of CHR participants (N = 370, mean age = 18.3) enrolled in the multisite North American Prodrome Longitudinal Study Phase 1 project. Three hundred and...
Yunong Bai, Simon N. Vandekar, Brandee Feola et al.
Abstract Objective Tobacco and cannabis are the most used substances among individuals at clinical high risk for psychosis (CHR-P), but it remains controversial whether substance use drives symptom exacerbation and psychosis transition, or vice versa. We investigated longitudinal dose-response relationships of tobacco and cannabis use with clinical presentation in a CHR-P population. Methods...
Carolyn M. Amir, Dara G. Ghahremani, Sarah E. Chang et al.
preprint
Abstract Importance Rates of prenatal cannabis exposure (PCE) are rising with increasingly permissive legislation regarding cannabis use, which may be a risk factor for psychosis. Disrupted reward-related neural circuitry may underlie this relationship. Objective To elucidate neural mechanisms involved in the association between PCE and youth-onset psychotic-like experiences by probing...